Authors
Latest:
Growing Body of Evidence Supports Use of HIPEC in Ovarian CancerA large pool of evidence exists to support the use of HIPEC in ovarian cancer, and hyperthermic and other novel intraperitoneal chemotherapies should continue to be incorporated into novel clinical trial designs.
Latest:
Dr. Welling on SIRT in Patients With Hepatobiliary NeoplasmsTheodore H. Welling MD, associate professor, department of Surgery, director, Liver Tumor Program, NYU Langone’s Perlmutter Cancer Center, discusses the use of selective internal radiation therapy (SIRT) in patients with hepatobiliary cancers.
Latest:
Dr. Hong on High-Dose Hypofractionated Proton Beam Therapy for Liver CancerTheodore S. Hong, MD, director, Gastrointestinal Service, Department of Radiation Oncology, discusses high-dose hypofractionated proton beam therapy for unresectable primary liver cancers.
Latest:
Second Cancers Can Wield Greater Impact on Adolescent and Young Adult SurvivorsAdvances in treatment and supportive care have resulted in substantial improvements in cancer survival and a growing number of cancer survivors in the United States.
Latest:
The C Letter WordHematology/oncology fellowship coordinator, Theresa Marcus, reflects on what it was like to receive a diagnosis of cancer, experience recurrence, and later learn that she had finally become cancer-free with the help of her colleagues.
Latest:
Dr. Shao on Prognosis of Patients With HER2+ Breast CancerTheresa Shao, MD, assistant professor of hematology-oncology, Icahn School of Medicine, Tisch Cancer Institute, Mount Sinai Health System, discusses the prognosis of patients with HER2-positive breast cancer.
Latest:
Dr Andre on the Efficacy of Nivolumab/Ipilimumab in MSI-H/dMMR mCRC SubgroupsThierry Andre, MD, discusses subgroup and safety analyses of the phase 3 CheckMate 8HW trial of frontline nivolumab plus ipilimumab in MSI-H/dMMR mCRC.
Latest:
Dr. Conroy on the Findings With Adjuvant mFOLFIRINOX in Pancreatic CancerThierry Conroy, MD, medical oncologist, director, Institut de Cancerologie de Lorraine, discusses the findings with an adjuvant a modified FOLFIRINOX regimen in patients with nonmetastatic pancreatic ductal adenocarcinoma.
Latest:
Dr. Thierry Jahan on CRS-207 With Chemotherapy in MesotheliomaThierry Jahan, MD, professor of medicine at the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, discusses CRS-20, a live, attenuated Listeria monocytogenes bacterium which is being investigated with chemotherapy in malignant pleural mesothelioma (MPM).
Latest:
Dr. Thierry Jahan on the CRS-207 Vaccine in MesotheliomaThierry M. Jahan, MD, a clinical professor in the Department of Medicine at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses a phase Ib trial of CRS-207 in malignant pleural mesothelioma (MPM).
Latest:
Dr. Abrams on Next Steps for Cabozantinib/Atezolizumab Combo in MSS/MMRp CRCThomas A. Abrams, MD, discusses the next steps for exploration of cabozantinib plus atezolizumab in the treatment of microsatellite stable and mismatch repair proficient colorectal cancer.
Latest:
Dr. Hensing Discusses Studies in Stage III NSCLCThomas A. Hensing, MD, co-director of the Thoracic Oncology Program at NorthShore University HealthSystem, discusses prospective studies in stage III non-small cell lung cancer (NSCLC).
Latest:
Dr. Hope on Challenges With 68Ga-PSMA-11 PET in Prostate CancerThomas Hope, MD, discusses challenges with 68Ga-PSMA-11 PET in men with intermediate- or high-risk prostate cancer.
Latest:
Thomas A. Neville, PhD, Discusses PSA Growth RateThomas A. Neville, PhD, CEO of Soar Biodynamics in Incline Village, Nevada, discusses PSA growth rate.
Latest:
Dr. Butler on the Importance of Health Literacy InitiativesThomas Butler, MD, associate professor of interdisciplinary clinical oncology, Mitchell Cancer Center, discusses the importance of health literacy initiatives at the Association of Community Cancer Center (ACCC) National Oncology Conference.
Latest:
Emerging ADCs in Advanced Endometrial Cancer: Anti-TROP2 and Anti-FR AgentsPanelists discuss recent data on emerging antibody-drug conjugates in advanced and recurrent endometrial cancer, including anti-TROP2 agents like sacituzumab govitecan from the TROPiCS-03 trial, datopotamab deruxtecan from TROPION-PanTumor03, and sacituzumab tirumotecan, as well as anti–folate receptor agents like luveltamab tazevibulin and rinatabart sesutecan, while offering future perspectives and closing thoughts on the evolving role of these agents in the treatment landscape for endometrial cancer.
Latest:
An Individualized Approach to Treating Advanced RCCGrounded in a collaborative and personalized approach, researcher and clinician Dr. Thomas Hutson expands on his best practices for treating certain people living with advanced RCC with a combination therapy.
Latest:
Series Wrap-up: Novel Therapies for mRCCA panel of expert oncologists who manage patients with renal cell carcinoma share enthusiasm over the use of newer novel-based treatment approaches for metastatic disease.
Latest:
Dr. Stinchcombe on the ALTA-1L Trial in ALK+ NSCLCThomas E. Stinchcombe, MD, discusses the results of the randomized phase III ALTA-1L trial in ALK-positive non–small cell lung cancer.
Latest:
Dr. Witzig on Emerging Agents in Diffuse Large B-Cell LymphomaThomas E. Witzig, MD, hematologist-oncologist, Mayo Clinic, discusses some of the emerging agents being utilized in the treatment of patients with diffuse large B-cell lymphoma.
Latest:
Dr Gajewski on the Role of the Gut Microbiome in Immunotherapy Response RegulationThomas F. Gajewski, MD, PhD, discusses the mechanism through which the gut microbiome modulates myeloid cells to regulate responses to immunotherapy.
Latest:
Dr. Martin on the Patient Population of the CARTITUDE-1 Study in R/R Multiple MyelomaThomas G. Martin, MD, discusses the patient population of the phase 2 CARTITUDE-1 study in relapsed/refractory multiple myeloma.
